Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Boehringer Ingelheim Pharmaceuticals |
---|---|
Information provided by: | Boehringer Ingelheim Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00618774 |
To assess the long term safety and efficacy of telmisartan plus amlodipine FDC in patients with essential hypertension who failed to control their BP with either monotherapy.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: telmisartan40/amlodipine5 Drug: telmisartan80/amlodipine5 |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Parallel Assignment, Safety/Efficacy Study |
Official Title: | An Open-Label, Long-Term Study of Telmisartan Plus Amlodipine Fixed-Dose Combination |
Estimated Enrollment: | 200 |
Study Start Date: | January 2008 |
Estimated Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 20 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Japan | |
1235.16.001 Boehringer Ingelheim Investigational Site | |
Shinjyuku-ku,Tokyo, Japan | |
1235.16.002 Boehringer Ingelheim Investigational Site | |
Suita, Osaka, Japan | |
1235.16.003 Boehringer Ingelheim Investigational Site | |
Shinjuku-ku, Tokyo, Japan | |
1235.16.007 Boehringer Ingelheim Investigational Site | |
Osaka, Osaka, Japan | |
1235.16.005 Boehringer Ingelheim Investigational Site | |
Osaka, Osaka, Japan | |
1235.16.006 Boehringer Ingelheim Investigational Site | |
Nishi-ku, Hiroshima, Hiroshima, Japan | |
1235.16.004 Boehringer Ingelheim Investigational Site | |
Chofu, Tokyo, Japan |
Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim Pharmaceuticals |
Responsible Party: | Boehringer Ingelheim ( Boehringer Ingelheim, Study Chair ) |
Study ID Numbers: | 1235.16 |
Study First Received: | February 8, 2008 |
Last Updated: | December 17, 2008 |
ClinicalTrials.gov Identifier: | NCT00618774 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Calcium, Dietary Vascular Diseases Telmisartan |
Angiotensin II Amlodipine Hypertension |
Vasodilator Agents Molecular Mechanisms of Pharmacological Action Calcium Channel Blockers Enzyme Inhibitors Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |
Protease Inhibitors Membrane Transport Modulators Angiotensin II Type 1 Receptor Blockers Therapeutic Uses Angiotensin-Converting Enzyme Inhibitors Cardiovascular Diseases |